Abstract
Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.
Original language | English |
---|---|
Pages (from-to) | S78-S103 |
Number of pages | 26 |
Journal | Seminars in Cancer Biology |
Volume | 35 |
DOIs | |
Publication status | Published - Dec 1 2015 |
Keywords
- Apoptosis
- Apoptosis evasion
- Autophagy
- Necrosis
- Nuclear transporters, natural chemopreventive agents
ASJC Scopus subject areas
- Cancer Research
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Broad targeting of resistance to apoptosis in cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Seminars in Cancer Biology, Vol. 35, 01.12.2015, p. S78-S103.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Broad targeting of resistance to apoptosis in cancer
AU - Mohammad, Ramzi M.
AU - Muqbil, Irfana
AU - Lowe, Leroy
AU - Yedjou, Clement
AU - Hsu, Hsue Yin
AU - Lin, Liang Tzung
AU - Siegelin, Markus David
AU - Fimognari, Carmela
AU - Kumar, Nagi B.
AU - Dou, Q. Ping
AU - Yang, Huanjie
AU - Samadi, Abbas K.
AU - Russo, Gian Luigi
AU - Spagnuolo, Carmela
AU - Ray, Swapan K.
AU - Chakrabarti, Mrinmay
AU - Morre, James D.
AU - Coley, Helen M.
AU - Honoki, Kanya
AU - Fujii, Hiromasa
AU - Georgakilas, Alexandros G.
AU - Amedei, Amedeo
AU - Niccolai, Elena
AU - Amin, Amr
AU - Ashraf, S. Salman
AU - Helferich, William G.
AU - Yang, Xujuan
AU - Boosani, Chandra S.
AU - Guha, Gunjan
AU - Bhakta, Dipita
AU - Ciriolo, Maria Rosa
AU - Aquilano, Katia
AU - Chen, Sophie
AU - Mohammed, Sulma I.
AU - Keith, W. Nicol
AU - Bilsland, Alan
AU - Halicka, Dorota
AU - Nowsheen, Somaira
AU - Azmi, Asfar S.
N1 - Funding Information: NIH Grants R21 1R21CA16984801 and 1R21CA17597401 to RMM is acknowledged. This work was partially supported by the Scientific Research Foundation for the Returned Oversea Scholars and State Education Ministry and Scientific and Technological Innovation Project, Harbin (2012RFLXS011 to HJ Yang), and NIH/NCI (1R01CA20009, 5R01CA127258-05 and R21CA184788 to Q.P. Dou, and NIH P30 CA22453 to Karmanos Cancer Institute). HY Hsu was funded by grants from the Ministry of Science and Technology of Taiwan (NSC93-2314-B-320-006 and NSC94-2314-B-320-002) and LT Lin was supported by a grant from Taipei Medical University (TMU101-AE3-Y19) NIH Grant K08 NS083732 to MDS is acknowledged. Dr. Gian Luigi Russo acknowledges the Fulbright Research Scholar program 2013-14. Work in CF''s lab described here was supported by Ministero dell’Istruzione dell’Università e della Ricerca (grant number: 200974K3JC). Dr. Clement G. Yedjou acknowledges NIH grant 5G12RR013459-13 through the RCMI-Center for Environmental Health at Jackson State University. Dr. Georgakilas was supported by an EU Marie Curie Reintegration Grant MC-CIG-303514, Greek National funds through the Operational Program ‘Educational and Lifelong Learning of the National Strategic Reference Framework (NSRF)-Research Funding Program: THALES (Grant number MIS 379346) and COST Action CM1201 ‘Biomimetic Radical Chemistry’. The work reported by Nagi B. Kumar was funded by the National Institute of Health – National Cancer Institute R01 CA12060-01A1. Work in Carmela Famignori''s lab described here was supported by Ministero dell’Istruzione dell’Università e della Ricerca (grant number: 200974K3JC). Dr. Swapan K Ray and Mrinmay Chakrabarti acknowledge the support by United Soybean Board (USB Chesterfield, M, United States). The USB had no involvement in the writing of the manuscript or the decision to submit the manuscript for publication. Amr Amin was supported partially by Al-Jalila Foundation 2015, Zayed Center for Health Sciences 2015, and Terry Fox Foundation 2014. NIH grant 1 R21 CA188818 01A1 to Asfar Azmi is acknowledged. Funding Information: NIH Grants R21 1R21CA16984801 and 1R21CA17597401 to RMM is acknowledged. This work was partially supported by the Scientific Research Foundation for the Returned Oversea Scholars and State Education Ministry and Scientific and Technological Innovation Project, Harbin ( 2012RFLXS011 to HJ Yang), and NIH/NCI ( 1R01CA20009 , 5R01CA127258-05 and R21CA184788 to Q.P. Dou, and NIH P30 CA22453 to Karmanos Cancer Institute). HY Hsu was funded by grants from the Ministry of Science and Technology of Taiwan ( NSC93-2314-B-320-006 and NSC94-2314-B-320-002 ) and LT Lin was supported by a grant from Taipei Medical University ( TMU101-AE3-Y19 ) NIH Grant K08 NS083732 to MDS is acknowledged. Dr. Gian Luigi Russo acknowledges the Fulbright Research Scholar program 2013-14. Work in CF's lab described here was supported by Ministero dell’Istruzione dell’Università e della Ricerca (grant number: 200974K3JC ). Dr. Clement G. Yedjou acknowledges NIH grant 5G12RR013459-13 through the RCMI-Center for Environmental Health at Jackson State University. Dr. Georgakilas was supported by an EU Marie Curie Reintegration Grant MC-CIG-303514 , Greek National funds through the Operational Program ‘Educational and Lifelong Learning of the National Strategic Reference Framework (NSRF)-Research Funding Program: THALES (Grant number MIS 379346 ) and COST Action CM1201 ‘Biomimetic Radical Chemistry’. The work reported by Nagi B. Kumar was funded by the National Institute of Health – National Cancer Institute R01 CA12060-01A1 . Work in Carmela Famignori's lab described here was supported by Ministero dell’Istruzione dell’Università e della Ricerca (grant number: 200974K3JC ). Dr. Swapan K Ray and Mrinmay Chakrabarti acknowledge the support by United Soybean Board (USB Chesterfield, M, United States). The USB had no involvement in the writing of the manuscript or the decision to submit the manuscript for publication. Amr Amin was supported partially by Al-Jalila Foundation 2015, Zayed Center for Health Sciences 2015, and Terry Fox Foundation 2014. NIH grant 1 R21 CA188818 01A1 to Asfar Azmi is acknowledged. Funding Information: NIH Grants R21 1R21CA16984801 and 1R21CA17597401 to RMM is acknowledged. This work was partially supported by the Scientific Research Foundation for the Returned Oversea Scholars and State Education Ministry and Scientific and Technological Innovation Project, Harbin (2012RFLXS011 to HJ Yang), and NIH/NCI (1R01CA20009, 5R01CA127258-05 and R21CA184788 to Q.P. Dou, and NIH P30 CA22453 to Karmanos Cancer Institute). HY Hsu was funded by grants from the Ministry of Science and Technology of Taiwan (NSC93-2314-B-320-006 and NSC94-2314-B-320-002) and LT Lin was supported by a grant from Taipei Medical University (TMU101-AE3-Y19) NIH Grant K08 NS083732 to MDS is acknowledged. Dr. Gian Luigi Russo acknowledges the Fulbright Research Scholar program 2013-14. Work in CF''s lab described here was supported by Ministero dell?Istruzione dell?Universit? e della Ricerca (grant number: 200974K3JC). Dr. Clement G. Yedjou acknowledges NIH grant 5G12RR013459-13 through the RCMI-Center for Environmental Health at Jackson State University. Dr. Georgakilas was supported by an EU Marie Curie Reintegration Grant MC-CIG-303514, Greek National funds through the Operational Program ?Educational and Lifelong Learning of the National Strategic Reference Framework (NSRF)-Research Funding Program: THALES (Grant number MIS 379346) and COST Action CM1201 ?Biomimetic Radical Chemistry?. The work reported by Nagi B. Kumar was funded by the National Institute of Health ? National Cancer Institute R01 CA12060-01A1. Work in Carmela Famignori''s lab described here was supported by Ministero dell?Istruzione dell?Universit? e della Ricerca (grant number: 200974K3JC). Dr. Swapan K Ray and Mrinmay Chakrabarti acknowledge the support by United Soybean Board (USB Chesterfield, M, United States). The USB had no involvement in the writing of the manuscript or the decision to submit the manuscript for publication. Amr Amin was supported partially by Al-Jalila Foundation 2015, Zayed Center for Health Sciences 2015, and Terry Fox Foundation 2014. NIH grant 1 R21 CA188818 01A1 to Asfar Azmi is acknowledged. Publisher Copyright: © 2015 Elsevier Ltd.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.
AB - Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.
KW - Apoptosis
KW - Apoptosis evasion
KW - Autophagy
KW - Necrosis
KW - Nuclear transporters, natural chemopreventive agents
UR - http://www.scopus.com/inward/record.url?scp=84928539179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928539179&partnerID=8YFLogxK
U2 - 10.1016/j.semcancer.2015.03.001
DO - 10.1016/j.semcancer.2015.03.001
M3 - Review article
C2 - 25936818
AN - SCOPUS:84928539179
SN - 1044-579X
VL - 35
SP - S78-S103
JO - Seminars in Cancer Biology
JF - Seminars in Cancer Biology
ER -